Adiponectin receptor C-terminal fragments (CTF)-immunoglobulin

Patent metadata

Field	Value
Publication number	US-9291629-B2
Application number	US-201214111506-A
Country	US
Kind code	B2
Filing date	Feb 22, 2012
Priority date	Apr 11, 2011
Publication date	Mar 22, 2016
Grant date	Mar 22, 2016

Abstract

Methods of detecting a first species' Ig-CTF in a biological sample comprising exposing the biological sample to a first antibody of a second species that preferentially binds the first species' Ig-CTF or an antigen binding fragment of the antibody, forming a mixture, exposing the mixture to a second antibody or antigen-binding fragment of a third species that preferentially binds the first species' Ig, and detecting the Ig-CTF in the biological sample.

First claim

What is claimed:

1. A method for detecting Ig-C-terminal fragment of adiponectin receptor (Ig-CTF) in a biological sample, said method comprising:
a. exposing a biological sample derived from a subject of a first species to a first antibody of a second species that preferentially binds the first species' Ig-CTF, said Ig-CTF comprising an immunoglobulin portion attached to a CTF peptide, said CTF peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 44, or an antigen-binding fragment of said first antibody, forming a mixture;
b. exposing said mixture to a second antibody or an antigen-binding fragment of a third species that preferentially binds the first species' Ig; and
c. detecting the Ig-CTF present in said sample.

2. A method of monitoring the level of Ig-C-terminal fragment of adiponectin receptor (Ig-CTF) in a subject of a first species, said method comprising:
a. detecting Ig-CTF in a biological sample of the subject by using the method as claimed in claim 1 ;
b. quantifying the amount of Ig-CTF present in said sample;
c. comparing the amount of Ig-CTF present in the sample to either
i. a known standard; or
ii. the amount of IgG-CTF present in a biological sample obtained from the subject at an earlier point in time.

3. The method of claim 1 wherein said immunoglobulin portion comprises an immunoglobulin, and immunoglobulin heavy chain, an immunoglobulin light chain, or an immunoglobulin fragment.

4. The method of claim 1 wherein said immunoglobulin portion comprises SEQ ID NO: 45 or SEQ ID NO: 46.

5. The method of claim 1 wherein said second antibody or antigen-binding fragment is detectably labeled.

6. The method of claim 3 wherein said immunoglobulin is isotype IgG, IgA, IgM, IgD, or IgE.

7. The method of claim 1 wherein the first antibody or antigen-binding fragment is bound to a solid support.

Assignees

• Pugia Michael
• Siemens Healthcare Diagnostics

Inventors

• Pugia Michael

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• G01N33/6854 Primary

  Immunoglobulins · CPC title

• G01N33/74

  involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title